3. FEV₁ network composition and transitivity assessment^a.

Comparison	Comparisons	N	Ageb	% male	%FEV1c	Packsd
LABA vs Placebo	13	8680	63.3	73.2	47.7	43.9
LAMA vs Placebo	16	23,111	64.3	72.2	47.6	48.9
ICS vs Placebo	12	4574	63.6	71.9	46.2	45.2
LABA/ICS vs Placebo	9	4978	63.9	73.5	41.6	44.4
LABA vs LAMA	2	2680	63.7	69.5	55.2	49.7
LABA vs ICS	5	2506	63.6	67.1	40.6	46.7
LABA vs LABA/ICS	12	8005	63.7	68.8	39.9	45.8
LAMA vs ICS	0	‐	‐	‐	‐	‐
LAMA vs LABA/ICS	0	‐	‐	‐	‐	‐
ICS vs LABA/ICS	8	4560	63.6	71.7	39.0	45.5

^aSummary population data are for all study comparisons excluding those made in the 23 studies that could not be included in either the six‐month or the 12‐month FEV₁ network; all doses are given in micrograms.

^bAge = mean years.

^c% FEV₁ = mean percentage predicted FEV₁.

^dPacks = mean pack‐years.

FEV1 = forced expiratory volume in one second.

ICS = inhaled corticosteroid.

LABA = long‐acting beta₂‐agonist.

LABA/ICS = long‐acting beta₂‐agonist/inhaled corticosteroid combination therapy.

LAMA = long‐acting muscarinic antagonist.